We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
Read MoreHide Full Article
In the latest market close, Johnson & Johnson (JNJ - Free Report) reached $155.77, with a +0.35% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.08%, and the Nasdaq, a tech-heavy index, lost 0.42%.
Shares of the world's biggest maker of health care products have depreciated by 3.46% over the course of the past month, underperforming the Medical sector's loss of 1.21% and the S&P 500's gain of 2.67%.
The investment community will be paying close attention to the earnings performance of Johnson & Johnson in its upcoming release. The company is slated to reveal its earnings on April 16, 2024. On that day, Johnson & Johnson is projected to report earnings of $2.64 per share, which would represent a year-over-year decline of 1.49%. Alongside, our most recent consensus estimate is anticipating revenue of $21.38 billion, indicating a 13.59% downward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.65 per share and a revenue of $88.38 billion, representing changes of +7.36% and -4.99%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Johnson & Johnson currently has a Zacks Rank of #3 (Hold).
Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 14.57. This indicates no noticeable deviation in contrast to its industry's Forward P/E of 14.57.
It is also worth noting that JNJ currently has a PEG ratio of 2.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.77 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 209, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
In the latest market close, Johnson & Johnson (JNJ - Free Report) reached $155.77, with a +0.35% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.08%, and the Nasdaq, a tech-heavy index, lost 0.42%.
Shares of the world's biggest maker of health care products have depreciated by 3.46% over the course of the past month, underperforming the Medical sector's loss of 1.21% and the S&P 500's gain of 2.67%.
The investment community will be paying close attention to the earnings performance of Johnson & Johnson in its upcoming release. The company is slated to reveal its earnings on April 16, 2024. On that day, Johnson & Johnson is projected to report earnings of $2.64 per share, which would represent a year-over-year decline of 1.49%. Alongside, our most recent consensus estimate is anticipating revenue of $21.38 billion, indicating a 13.59% downward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.65 per share and a revenue of $88.38 billion, representing changes of +7.36% and -4.99%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Johnson & Johnson currently has a Zacks Rank of #3 (Hold).
Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 14.57. This indicates no noticeable deviation in contrast to its industry's Forward P/E of 14.57.
It is also worth noting that JNJ currently has a PEG ratio of 2.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.77 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 209, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.